MAIA Biotechnology, Inc. MAIA
1.03 USD -0.02 (-1.90%)
At closeNov 12, 2026, 8:32 AM EST
1.03 0.00 +0.02%
Pre-market · Nov 12, 8:32 AM ET
1.03 Day range 1.09
0.87 52-week range 3.19
- YTD
- -32.68%
- 1 year
- -8.04%
News
benzinga.com Alpha Buying: 4 Biotech Stocks Insiders Are Betting On I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
benzinga.com MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached…
benzinga.com MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder")…
benzinga.com MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer THIO-104 advances toward key 2027 interim survival analysisCHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
benzinga.com MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3…- benzinga.com MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…- benzinga.com MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of…
benzinga.com MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer 90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily…- benzinga.com MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
benzinga.com MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment…- benzinga.com MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDAFDA-cleared IND updates detail latest efficacy data and enriched…
- benzinga.com MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were…
benzinga.com MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of…- benzinga.com MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
- benzinga.com MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial; Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage…
- benzinga.com MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of…
- benzinga.com Is the Market Bullish or Bearish on MAIA Biotechnology Inc?
benzinga.com Crude Oil Surges Over 6%; Target Profit Tops Views US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vessels. Dow down 2.45%, NASDAQ down 2.62%, S&P 500 down 2.34%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Dips 900 Points; Best Buy Posts Upbeat Earnings U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tuesday amid the ongoing Iran-U.S. conflict. Iranian state media reported that Tehran has closed the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quar- benzinga.com MAIA Biotechnology Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; No Size Disclosed MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commenced an…
- benzinga.com MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update…
- benzinga.com MAIA Biotechnology Announces $1.51M Private Placement Of 1.23M At A Price Of $1.224/Share With Warrants Exercisable At A Price Of $1.36/Share MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into…
- benzinga.com MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapyCHICAGO, Dec. 11, 2025 (GLOBE…
- benzinga.com MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and…
- benzinga.com MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countriesPosters for Phase 2 and Phase 3 clinical trials availableCHICAGO , Nov. 21, 2025 (GLOBE…
benzinga.com MAIA Biotechnology Reports Efficacy Of Ateganosine In High-Risk Non-Small Cell Lung Cancer At ESMO 2025 Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a…- benzinga.com MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC)CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com MAIA Biotechnology Receives $2.3M NIH Grant To Expand THIO-101 Phase 2 Trial For Advanced Lung Cancer In U.S. THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)CHICAGO, Sept. 24, 2025 (GLOBE…
- benzinga.com MAIA Biotechnology Highlights Efficacy Data From Phase 2 Clinical Trial, THIO-101, Evaluating Ateganosine Sequenced With Immune CPI Cemiplimab In Patients With Advanced NSCLC MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy…
- benzinga.com MAIA Biotechnology To Present Phase 2 THIO + Cemiplimab Data In ICI-Resistant aNSCLC At IASLC WCLC 2025; Poster Highlights PFS Improvement Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA",…
- benzinga.com MAIA Biotechnology's Phase 2 THIO-101 Trial Developments Published In Cells Journal MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript…
- benzinga.com MAIA Biotechnology Q2 EPS $(0.18) Beats $(0.24) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 55 percent increase over losses of $(0.40)…
- benzinga.com MAIA Biotechnology Announces FDA Fast Track For First-in-Class Telomere-Targeting Drug In NSCLC; Latest Data In Pivotal Phase 2 THIO-101 Clinical Trial Shows Median Overall Survival Of 17.8 Months Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment marketLatest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of…
- benzinga.com MAIA Biotechnology Doses First Patient In Taiwan In Expansion Phase Of THIO-101 Phase 2 Trial For Advanced Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in…
- benzinga.com MAIA Biotechnology To Present Data Highlighting Cancer Telomere-Targeting Agent And Next-Generation Treatments, At FEBS 2025 MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster…
- benzinga.com MAIA Biotechnology Enters Into Clinical Master Supply Agreement With Roche For Future Studies Investigating Combination Of MAIA's THIO, Sequenced With Roche's CPI, Atezolizumab For Cancer Treatments Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatmentsMAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage…
benzinga.com MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.- benzinga.com MAIA Biotechnology Says New Partial Response Identified In Patient After 20 Months Of Treatment In Phase 2 THIO-101 Clinical Trial Evaluating Ateganosine, Sequenced With Regeneron's Immune CPI Libtayo In NSCLC Patients MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial…
- benzinga.com MAIA Biotechnology Reports Updated Phase 2 THIO-101 Trial Data Showing Median Overall Survival Of 17.8 Months With Ateganosine Plus Cemiplimab In Heavily Pre-Treated NSCLC Patients Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest dataMAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical…
- benzinga.com MAIA Biotechnology Announces Private Placement of 446,332 Shares At $1.50/Shr MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into…